{"transactions":[{"id":1473330,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-20T16:30:09.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":16188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three equal annual installments beginning on June 17, 2025."}],"balance_after":16188,"derivative":{"exercise_price":82.63,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":16188},"source":{"system":"sec-edgar","filing":"0000950170-24-075627","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000095017024075627/ownership.xml","form_type":"4"}},{"id":1473329,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-20T16:30:09.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":9076,"price":82.63,"value":749949.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 9,076 restricted stock units that vest in equal installments over a three-year period."}],"balance_after":9076,"source":{"system":"sec-edgar","filing":"0000950170-24-075627","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000095017024075627/ownership.xml","form_type":"4"}},{"id":2028777,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T16:43:21.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":14150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on February 3, 2024, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date."}],"balance_after":14150,"derivative":{"exercise_price":1.69,"expiration_date":"2033-02-03","underlying":"Common Stock","underlying_shares":14150},"source":{"system":"sec-edgar","filing":"0001209191-23-007544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000120919123007544/doc4.xml","form_type":"4"}},{"id":2199135,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-01T21:14:49.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022."}],"balance_after":75000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-027272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924322027272/doc4.xml","form_type":"4"}},{"id":2264004,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T16:23:41.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022."}],"balance_after":50000,"derivative":{"exercise_price":1.18,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-22-018819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924322018819/doc4.xml","form_type":"4"}},{"id":2375025,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-24T17:00:41.000Z","date":"2022-02-22","kind":"grant","acquired":true,"shares":2358,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in full on February 22, 2023, subject to the Reporting Person's continued service to the board of directors of the Company through the applicable vesting date."}],"balance_after":2358,"derivative":{"exercise_price":5.96,"expiration_date":"2032-02-22","underlying":"Common Stock","underlying_shares":2358},"source":{"system":"sec-edgar","filing":"0000899243-22-007648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924322007648/doc4.xml","form_type":"4"}},{"id":2388800,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-17T17:22:45.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022."}],"balance_after":75000,"derivative":{"exercise_price":3.19,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-006824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924322006824/doc4.xml","form_type":"4"}},{"id":2470041,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-16T16:35:12.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":28300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of December 15, 2021, subject to the Reporting Person's continued service to the board of directors of the Issuer through the applicable vesting date."}],"balance_after":28300,"derivative":{"exercise_price":10.75,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":28300},"source":{"system":"sec-edgar","filing":"0000899243-21-048612","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924321048612/doc4.xml","form_type":"4"}},{"id":2552311,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-04T16:34:18.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exerciseable over four years, with 25% of this option vesting on October 1, 2022, and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":275000,"derivative":{"exercise_price":7.51,"expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000899243-21-038823","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000089924321038823/doc4.xml","form_type":"4"}},{"id":2630735,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2021-07-19T18:45:00.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":35055,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":35.5,"underlying":"Common Stock","underlying_shares":35055},"source":{"system":"sec-edgar","filing":"0001562180-21-004988","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000156218021004988/primarydocument.xml","form_type":"4"}},{"id":2630734,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T18:45:00.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":133000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":30.2,"underlying":"Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001562180-21-004988","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000156218021004988/primarydocument.xml","form_type":"4"}},{"id":2850804,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-18T16:53:10.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":35055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2021, and the shares underlying the option vest in equal quarterly installments through February 16, 2025, subject to continued service."}],"balance_after":35055,"derivative":{"exercise_price":35.5,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":35055},"source":{"system":"sec-edgar","filing":"0001562180-21-001265","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000156218021001265/primarydocument.xml","form_type":"4"}},{"id":3086776,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":89724,"kind":"person","name":"Humphrey Jeffrey","position":1,"cik":"0001816944","reported_name":"Humphrey Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-07-08T16:48:27.000Z","date":"2020-07-07","kind":"grant","acquired":true,"shares":133000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 7, 2020, and is scheduled to vest as to 25% of the shares underlying the option on July 7, 2021 with the remainder vesting in equal quarterly installments through July 7, 2024, subject to continued service."}],"balance_after":133000,"derivative":{"exercise_price":30.2,"expiration_date":"2030-07-06","underlying":"Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001562180-20-005078","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816944/000156218020005078/primarydocument.xml","form_type":"4"}}]}